Cardinal Health extends CVS deal through 2032: what it means for Cardinal Health stock

Published on 10/14/2026 at 09:31 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Cardinal Health stock costs EUR 213.90 on October 14, 2026 at Lang & Schwarz. Fiscal 2026 revenue reached USD 254.2 billion.

CVS agreement and fiscal growth

Cardinal Health extended its CVS distribution agreement through June 30, 2032, on October 1, 2026.
Fiscal 2027 non-GAAP earnings per share guidance is 13.00 percent to 15.00 percent growth.
Cardinal Health stock traded at EUR 213.90 at 9:29 a.m. CEST at Lang & Schwarz on October 14, 2026.

CGI-Render moderner Unternehmensgebäude mit Glasfassade und Außenanlage in Dublin Ohio — Architektur-Render des Cardinal Health Inc. Hauptsitzes in Dublin, Ohio – ISIN US14149Y1082, Illustration mit AI erstellt.

Cardinal Health (ISIN US14149Y1082) traded at EUR 213.90 at Lang & Schwarz at 9:29 a.m. CEST on October 14, 2026. On October 1, 2026, Cardinal Health extended its pharmaceutical distribution agreement with CVS Health through June 30, 2032, while reaffirming fiscal 2027 non-GAAP earnings per share growth guidance of 13.00 percent to 15.00 percent, according to Cardinal Health.

What does the CVS extension change?

The agreement keeps Cardinal Health's existing distribution scope with CVS in place through June 30, 2032. The same October 1 release set fiscal 2027 non-GAAP earnings per share guidance at USD 12.40 to USD 12.60 and retained the long-term growth range of 12.00 percent to 14.00 percent.

That combination gives the announcement two distinct dimensions: contract duration and earnings visibility. The CVS term reaches beyond the current fiscal year, while the guidance range points to continued expansion from the fiscal 2026 base.

Fiscal 2026 delivered higher cash flow

Cardinal Health reported USD 254.2 billion of revenue in fiscal 2026, up 14.00 percent year over year. GAAP operating earnings rose 15.00 percent to USD 2.6 billion, while operating cash flow increased 116.00 percent to USD 5.2 billion, according to StockTitan in its September 21, 2026 filing summary.

The cash-flow figure matters because it provides a stronger internal funding base for specialty expansion, acquisitions and shareholder returns. The filing also reported GAAP diluted earnings per share of USD 7.23 for fiscal 2026, up 12.00 percent year over year, with the comparison period ending June 30, 2025.

Three dated company milestones

On April 30, 2026, Cardinal Health reported third-quarter fiscal 2026 revenue of USD 60.9 billion and raised its outlook, according to Cardinal Health. On August 11, 2026, it reported fourth-quarter revenue of USD 63.7 billion, up 6.00 percent, and fiscal 2026 results. The October 1 CVS agreement is the latest of the three dated milestones.

Upcoming reporting date

Cardinal Health plans to release first-quarter fiscal 2027 results on November 5, 2026, before trading opens on the New York Stock Exchange, according to Cardinal Health. The company will discuss the results at 8:30 a.m. Eastern time.

Stock trades in morning session

Cardinal Health stock was trading at EUR 213.90 at Lang & Schwarz on October 14, 2026 at 9:29 a.m. CEST, during the Xetra session. The finance quote for Cardinal Health showed a USD 56.1 billion market capitalization, with a USD 152.46 to USD 258.30 52-week range as of October 13, 2026.

The further course of trading is shown by the continuously updated real-time quote of Cardinal Health stock.